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serum parathyroid hormone (PTH) concentrations. Fol-
lowing vitD3 supplementation, there was an overall rise in 
24-h urine calcium excretion, but it failed to reach statisti-
cal significance (p = 0.06). U. Calcium/Cr increased in 22 
out of 37 patients (average increase +0.07 mmol/mmol), 
decreased in 14 (average decrease −0.13 mmol/mmol), and 
remained unchanged in 1; 6 out of 26 initially normocal-
ciuric ISF developed hypercalciuria; and 6 out of 9 patients 
who became vitD replete were hypercalciuric after supple-
mentation. It is appropriate to monitor urinary Ca excretion 
in vitD-supplemented stone formers, because it may reveal 
underlying hypercalciuria in some treated patients.
Keywords Calcium · Kidney · Nephrolithiasis · Renal 
stones · Vitamin D
Introduction
Although vitamin D (vitD) deficiency worldwide is com-
mon [1, 2] diseases, such as rickets and osteomalacia, 
which occur with severe and prolonged vitD deficiency, 
are still uncommon in Europe and the US. However, there 
is growing concern that changes in our diet—especially 
in northern Europe, where there is less sunshine—and 
publicity over the risk of UV-related skin cancer is lead-
ing to more prevalent vitD deficiency. Moreover, there is 
increasing awareness of the skeletal (non-osteomalacic) 
and potential non-skeletal consequences of vitD deficiency. 
Though still controversial, observational, and epidemio-
logical studies have found associations between low serum 
25-OH vitD with lower bone mineral density [3] and osteo-
porosis, colorectal carcinoma [4], prostate cancer [5], con-
gestive heart failure [6], insulin resistance and type 2 dia-
betes [7], and even an increased risk of schizophrenia and 
Abstract While vitamin D (vitD) deficiency is thought to 
contribute to poor health in a variety of ways and should 
be corrected, there is still concern about giving vitD sup-
plements to patients with a history of nephrolithiasis. The 
aim is to study the prevalence of vitD deficiency and the 
effect on stone risk of cholecalciferol (vitD3) supple-
mentation in a cohort of idiopathic stone formers (ISF). 
We screened for vitD deficiency and urinary measures of 
stone risk, comparing vitD deficient (serum 25-OH vitD 
≤30 nmol/L; ≤12 ng/mL) with vitD insufficient (31–
75 nmol/L; 13–30 ng/mL) or vitD replete (>75 nmol/L; 
>30 ng/mL); we investigated the effect of giving vitD3 
(20,000 IU orally, weekly for 4 months) to 37 of the vitD 
deficients. Thirty-one percent (142/456) were vitD defi-
cient, 57% (259/456) vitD insufficient, and the rest (12%) 
vitD replete (55/456). Comparison among the groups 
showed that baseline 24-h urinary measures related to stone 
risk expressed as concentration ratios over urine creatinine 
(Cr), such as U. Calcium/Cr, U. Oxalate/Cr, U. Citrate/Cr, 
and U. Uric acid/Cr were not significantly different. VitD3 
supplementation did significantly increase serum 25-OH 
vitD levels and U. Phosphate/Cr ratios, as well as reduce 
 * Linda Shavit 
 lshavit@szmc.org.il
1 UCL Centre for Nephrology, Department of Clinical 
Biochemistry, Royal Free Campus and Hospital, Rowland 
Hill Street, London NW3 2PF, UK
2 Division of Nephrology, Department of Medical Sciences, 
Gemelli University Hospital, Catholic University of the 
Sacred Heart, Rome, Italy
3 Adult Nephrology Unit, Shaare Zedek Medical Center, 
Jerusalem, Israel
4 Nuffield Department of Surgical Sciences, University 
of Oxford, Oxford, UK
 Urolithiasis
1 3
depression [8]. Increased vitD intake has been associated 
with a reduced risk of vertebral and non-vertebral fractures 
[9], improved skeletal muscle function, and reduced rate of 
falls in the elderly [9], although a recent meta-analysis has 
challenged this [10]. A reduced risk of colorectal [11] and 
breast [12] cancers, reduced risk of multiple sclerosis [13], 
and of developing type 1 diabetes in children [14] have 
also been suggested after vitD supplementation. Indeed, 
because widespread vitD deficiency has been documented 
recently the UK, vitD supplementation has even been pro-
posed as a public health measure.
Patients with nephrolithiasis often have lower bone min-
eral density compared with the general population [15], 
especially in the lumbar spine, and they are at greater risk 
of fractures later in life. Kidney stones are also associ-
ated with a higher incidence of metabolic syndrome and 
increased cardiovascular risk [16], and so vitD-deficient 
patients with renal stones might benefit from vitD supple-
mentation; however, there is a general reluctance to give 
vitD to patients with a history of renal stones.
The prevalence of vitD deficiency in idiopathic stone 
formers (ISF) and whether such patients would have an 
increased stone risk if treated with vitD has not been inves-
tigated in detail. Any increased risk is thought to come 
from vitD-stimulated intestinal absorption of calcium and 
a resulting increase in urinary calcium excretion. However, 
there are no published data linking vitD supplementation 
alone to increased stone risk in the general population, 
and a study in 29 kidney stone patients given ergocalcif-
erol (vitD2) supplementation reported little or no change in 
calcium excretion [17]. Moreover, a recent study in post-
menopausal women given vitD to correct mild deficiency 
(mean serum 25-OH vitD level 40 nmol/L; 16 ng/mL) 
found only a small effect on intestinal calcium absorption 
[18]. In contrast, a prospective fracture prevention study in 
post-menopausal women has reported an increased risk of 
kidney stones in patients on vitD supplements, but those 
women were also given additional calcium (calcium car-
bonate 1000 mg daily) [19]. Calcium supplements alone 
have been linked to increased stone risk [20], confounding 
any effect of vitD alone.
Although there are case reports linking vitD toxic-
ity to renal stones, these were associated with significant 
hypercalcaemia, which does not occur when supplement-
ing vitD-deficient individuals with cholecalciferol (vitD3). 
However, while a recent report by Taylor et al. has linked 
baseline 1,25-(OH)2 vitD levels to increased stone risk in 
incident stone formers [21], we still do not know whether 
treatment of vitD deficiency with 25-OH vitD alters urine 
composition in line with increased stone risk. Therefore, 
we decided to evaluate the prevalence of vitD deficiency 
in renal stone formers and to examine for any changes in 
urine composition associated with vitD3 supplementation 
in a subgroup of vitD-deficient patients.
Methods
We estimated the prevalence of vitD deficiency (serum 
25-OH vitD ≤30 nmol/L) [22] in our large cohort of renal 
stone formers. The cohort included renal stone patients 
seen and investigated in our stone clinic over a period of 
4 years (from 2006 to 2010). Only idiopathic stone form-
ers (ISF) were included in the analysis, and anyone with a 
known secondary cause (cystinuria, primary hyperparathy-
roidism, primary or secondary hyperoxaluria, distal renal 
tubular acidosis, medullary sponge kidney, Dent’s disease, 
or on interfering medications) was excluded. In our rou-
tine protocol, which included the systematic measurement 
of 25-OH vitD concentration in serum, we compared the 
population characteristics and measurements made in the 
serum and urine of those patients who were vitD defi-
cient (serum 25-OH vitD ≤30 nmol/L; ≤12 ng/mL) with 
those who were vitD insufficient (serum 25-OH vitD 
>30 nmol/L and ≤75 nmol/L; >12 ng/mL and ≤30 ng/
mL) and vitD replete (serum 25-OH vitD >75 nmol/L; 
>30 ng/mL) [23]. However, it should be noted that while 
these particular cut-off values for vitD status are widely 
accepted, they are still debated [22]. For instance, the 
Institute of Medicine in the United States defines as vitD-
deficient patients, whose serum 25-OH vitD level is less 
than 20 nmol/L (<8 ng/mL).
In addition to giving common-sense dietary advice rel-
evant to the individual diet histories as well as biochemi-
cal results of the individual work-ups, we non-randomly 
supplemented with vitD3 those ISFs who were found to 
be vitD-deficient according to the criteria given above, and 
who consented verbally to treatment, a procedure which 
was approved by the Internal Review Board of our Institu-
tion. Forty-four of them were prescribed vitD3, 20,000 IU 
to be taken orally (as a capsule) once a week for 4 months, 
of which 37 (21 M, 16 F) completed this duration of sup-
plementation. No change in other medication potentially 
affecting urinary calcium took place during that time. 
Blood samples were taken and 24-h urine collections made 
pre- and post-vitD3 supplementations, and the results com-
pared. All the measurements were made in a biochemistry 
laboratory accredited to Clinical Pathology Accreditation 
standards. Serum 25-OH vitD levels were measured using 
a competitive immunoluminometric assay on the DiaSorin 
LIAISON platform (interassay coefficient of variation of 
7.3–17.5%); the laboratory technician responsible was una-
ware of the patient status in the study. Urinary oxalate and 
citrate were measured by enzymatic assays, and the rest of 
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the analytes, including parathyroid hormone (PTH), were 
measured on the Roche modular platform. To mitigate the 
risk of incorporation of incomplete or over-complete 24-h 
urine collections, urinary measurements were also factored 
by creatinine: a value of 0.6 mmol/mmol creatinine was 
taken as the upper normal limit for calcium in 24-h urine 
[24].
Statistical analysis
Summary measures are reported as means and standard 
deviations for continuous variables and frequencies and 
percentages for nominal variables. Differences among vitD 
status groups were analyzed by ANOVA. Pre–post differ-
ences after vitD supplementation were tested with paired 
t tests. A two-tailed p value <0.05 was considered statisti-
cally significant.
Results
Prevalence of vitD deficiency in ISF, and comparison 
of the serum and urinary measures made in vitD 
deficient, vitD insufficient, and vitD replete ISF
Four hundred and fifty-six ISF of mixed ethnicity (70% 
white and 30% non-white) were included, and 67% 
were males and 33% females, aged 17–81, and mean 
age 46.9 years. Thirty-one percent of these patients were 
vitD deficient (serum 25-OH vitD 20.4 ± 5.6 nmol/L; 
8.2 ± 2.2 ng/mL), while 57% were vitD insufficient 
(48.9 ± 12.3 nmol/L; 19.6 ± 4.9 ng/mL), and the rest 
(12%) classified as vitD replete (97.4 ± 22.4 nmol/L; 
39.0 ± 9.0 ng/mL). The groups were not significantly dif-
ferent in age, renal function, or body mass index (BMI). 
Subsequent comparisons among the three groups are 
arranged in the order: deficient, insufficient, and replete. 
Serum PTH levels were significantly different (4.87 ± 2.61, 
3.86 ± 2.01, and 3.25 ± 1.35 pmol/L)—Table 1. Multiple 
correlation studies revealed no association between 24-h 
urine excretion rates of calcium, oxalate, citrate, phosphate 
or urinary pH, respectively, and serum 25-OH vitD. We 
also looked at the seasonal variation in the prevalence of 
vitD deficiency in this cohort. Results are shown in Fig. 1 
and discussed below. 
Comparisons before and after vitD3 supplementation
All parameters routinely recorded before and after 
vitD3 supplementation are depicted in Table 2. Serum 
25-OH vitD levels were significantly higher (52.7 ± 26.6 
vs. 19.4 ± 5.7 nmol/L; p < 0.01) and PTH levels sig-
nificantly lower (4.61 ± 1.95 vs. 5.91 ± 3.28 pmol/L; 
p < 0.01) following vitD3 supplementation. Ten individu-
als remained vitD deficient after supplementation (27.0%), 
18 were insufficient (48.6%), and 9 replete (24.3%). 
No significant differences were found before and after 
vitD3 supplementation in serum calcium (2.20 ± 0.08 
vs. 2.21 ± 0.10 mmol/L: p = 0.56), serum phosphate 
(1.04 ± 0.16 vs. 1.02 ± 0.14 mmol/L; p = 0.57), and 
serum creatinine (87.3 ± 30.0 vs. 85.1 ± 27.7 umol/L; 
p = 0.24) concentrations. Similarly, no significant dif-
ferences were seen in U. Oxalate/Cr (29.3 ± 13.4 vs. 
31.3 ± 10.6 umol/mmol; p = 0.43) and U. Citrate/Cr 
(0.20 ± 0.12 vs. 0.20 ± 0.15 mmol/mmol; p = 0.80) pre- 
and post-vitD3 supplementations, respectively. Twenty-
four hour U. Uric acid/Cr ratio was significantly lower 
(0.25 ± 0.06 vs. 0.28 ± 0.07 mmol/mmol; p < 0.01) and 
U. Phosphate/Cr ratio significantly higher (2.27 ± 0.58 vs. 
2.05 ± 0.46 mmol/mmol; p = 0.02) post-supplementation. 
Twenty-four hour urinary sodium and volume did not sig-
nificantly change between pre- and post-supplementations. 
For U. Calcium/Cr, the pre- and post-supplementation dif-
ferences were only borderline non-significant (0.44 ± 0.31 
Table 1  Comparison of variables among 25-OH Vitamin D (VitD) deficient, VitD insufficient, and VitD replete within the renal stone popula-
tion
Groups/variables compared VitD deficient (N = 142) VitD insufficient (N = 259) VitD replete (N = 55) p value
Age (years) 44.9 ± 13.4 47.8 ± 15.1 47.6 ± 14.3 0.15
Body mass index (kg/m2) 26.8 ± 5.4 27.5 ± 5.7 25.6 ± 4.2 0.07
S. Creatinine (µmol/L) 83.4 ± 29.7 86.5 ± 24.3 86.1 ± 23.4 0.49
S. Calcium (mmol/L) 2.31 ± 0.09 2.33 ± 0.09 2.33 ± 0.09 0.10
S. Parathyroid Hormone (pmol/L) 4.87 ± 2.61 3.86 ± 2.01 3.25 ± 1.35 <0.01
U. Calcium/Cr (mmol/mmol) 0.41 ± 0.25 0.44 ± 0.25 0.44 ± 0.22 0.34
U. Oxalate/Cr (umol/mmol) 29.5 ± 9.2 27.9 ± 8.2 28.4 ± 9.0 0.24
U. Citrate/Cr (mmol/mmol) 0.20 ± 0.13 0.21 ± 0.11 0.21 ± 0.10 0.95
U. Phosphate/Cr (mmol/mmol) 1.98 ± 0.52 2.03 ± 0.57 2.05 ± 0.57 0.57
U. Uric acid/Cr (mmol/mmol) 0.27 ± 0.07 0.26 ± 0.07 0.25 ± 0.07 0.28
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vs. 0.51 ± 0.33 mmol/mmol; p = 0.06); however, when 
analyzed in subgroups according to the baseline urinary 
calcium excretion, we found a significant increase for those 
with a baseline U. Calcium/Cr ≤ 0.60 mmol/mmol (from 
0.28 ± 0.16 to 0.40 ± 0.25 mmol/mmol; p < 0.01), whereas 
the difference was not significant for those with baseline U. 
Calcium/Cr >0.60 mmol/mmol (U Calcium/Cr changed 
from 0.84 ± 0.21 to 0.78 ± 0.39 mmol/mmol; p = 0.50; 
p value for interaction = 0.02). Post-supplementation U. 
Calcium/Cr remained higher among those with high base-
line urine calcium excretion (on average by 0.38 mmol/
mmol, 95% confidence interval 0.17, 0.59; p < 0.01). Indi-
vidual paired values of U. Calcium/Cr are given in Fig. 2. 
It is apparent that among the 37 individuals who were sup-
plemented with vitD3 for 4 months, urinary calcium rose 
in 22, it decreased in 14 and remained unchanged in 1; 
of those 22 patients in whom urinary calcium rose after 
supplementation, 5 were hypercalciuric (defined as 24-h 
urinary Calcium/Cr ≥0.6 mmol/L) at baseline (group 1), 11 
were normocalciuric (and remained normocalciuric; group 
2), and 6 became hypercalciuric (from being normocal-
ciuric at baseline; group 3). Table 3 shows a comparison 
of variables amongst these three groups. Therefore, six 
normocalciuric individuals developed hypercalciuria fol-
lowing the vitD supplementation (while three individu-
als who were hypercalciuric at the baseline went the other 
way, i.e., turned normocalciuric). Figure 3 shows a scatter 
plot of the change from baseline in 24-h U. Ca/Cr vs. the 
corresponding change in 25-OH vitamin D concentration 
following vitD3 treatment indicates a positive correlation 
between these measurements. Figure 4 depicts a similar 
plot of the change from baseline in 24-h U. In phosphate/Cr 
vs. change in serum 25-OH vitD concentration, however, 
there is no correlation. A comparison of variables among 
Fig. 1  Seasonal variation in the 
prevalence of 25-OH vitamin D 
deficiency in idiopathic stone 
formers. N  number of patients 
in each season category
Table 2  Changes in serum and 
urinary analytes pre- and post-
vitD3 supplementations
Groups/variables compared Pre-supplementation Post-supplementation p value
S. 25-OH vitD (nmol/L) 19.4 ± 5.7 52.7 ± 26.6 <0.01
S. PTH (pmol/L) 5.91 ± 3.28 4.61 ± 1.95 <0.01
S. Creatinine (umol/L) 87.3 ± 30.0 85.1 ± 27.7 0.24
S. Calcium (mmol/L) 2.20 ± 0.08 2.21 ± 0.10 0.56
S. Phosphate (mmol/L) 1.04 ± 0.16 1.02 ± 0.14 0.57
U. Urea/Cr (mmol/mmol) 31.03 ± 7.50 31.86 ± 8.08 0.33
U. Calcium/Cr (mmol/mmol) 0.44 ± 0.31 0.51 ± 0.33 0.06
U. Oxalate/Cr (umol/mmol) 29.3 ± 13.4 31.3 ± 10.6 0.43
U. Citrate/Cr (mmol/mmol) 0.20 ± 0.12 0.20 ± 0.15 0.80
U. Phosphate/Cr (mmol/mmol) 2.05 ± 0.46 2.27 ± 0.58 0.02
U. Uric acid/Cr (mmol/mmol) 0.28 ± 0.07 0.25 ± 0.06 <0.01
U. Sodium/Cr (mmol/mmol) 13.23 ± 4.80 13.03 ± 8.45 0.97
U. Volume (L/24 h) 1.91 ± 0.70 2.15 ± 0.69 0.10
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Fig. 2  Comparison of 24-h uri-
nary Calcium/Cr ratio pre- and 
post-vitD3 supplementations 
in individual patients. Charts A 
(N = 26) and B (N = 11) depict 
patients with baseline U. Ca/
Cr <0.6 and ≥0.6, respectively. 
Markers in red and the red line 
depict mean values and mean 
change, respectively
Table 3  Details on the 22 patients, where U. Calcium/Cr increased after vitD supplementation
Group 1 includes individuals, where U Ca/Cr increased from within hypercalciuric range (U Ca/Cr ≥0.6 mmol/mmol), Group 2 includes indi-
viduals, where U Ca/Cr ratio increased and remained within normocalciuric range, and Group 3 includes individuals, where U Ca/Cr ratio 
increased from normocalciuria to hypercalciuric range
Group 1 (N = 5) Group 2 (N = 11) Group 3 (N = 6)
Age 52.6 ± 8.4 46.8 ± 10 62.5 ± 9
BMI 27.3 ± 3.9 29.9 ± 4.8 26.9 ± 6.1
M:F 2:3 5:6 2:4
White:non-white 0:5 8:3 4:2
Baseline serum 25-OH vitD (nmol/L) 19.2 ± 7.5 18.4 ± 4.5 18.1 ± 8.7
Baseline serum PTH (pmol/L) 5.2 ± 2.1 6.5 ± 4.0 5.8 ± 3.7
Baseline U. Calcium/Cr (mmol/mmol) 0.86 ± 0.2 0.20 ± 0.1 0.39 ± 0.1
Post supplement serum 25-OH vitD (nmol/L) 61.6 ± 26.2 51.3 ± 30.1 72.5 ± 29.3
Post-supplementation serum PTH (pmol/L) 3.6 ± 0.9 4.7 ± 1.6 4.0 ± 1.0
Post-supplementation U. Ca/Cr (mmol/mmol) 1.03 ± 0.40 0.34 ± 0.15 0.76 ± 0.13
Numbers deficient/insufficient/replete post-supplementation 1/2/2 4/6/1 1/2/3
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individuals who remained vitD-deficient post-supplemen-
tation (N = 10), became only insufficient (N = 18), and 
successfully became replete (N = 9), as given in Table 4. 
There were no significant differences between the groups 
in terms of age, BMI, and ethnicity. Baseline serum PTH 
levels and U. Calcium/Cr concentration ratio were also not 
Fig. 3  Change in 24-h U. 
Calcium/Cr ratio vs. change in 
serum 25-OH vitD-level post-
vitD3 supplementation
Fig. 4  Change in 24-h U 
phosphate/Cr ratio vs. change 
in serum 25-OH vitD-level post-
vitD3 supplementation. The 
correlation was not significant
Table 4  Comparison of variables among individuals who remained deficient post-supplementation (group 1) became insufficient (group 2) and 
became replete (group 3)
Group 1 (N = 10) Group 2 (N = 18) Group 3 (N = 9) p value
Males:females 6:4 14:4 2:7
Age (years) 54.1 ± 12.6 49.2 ± 10.0 49.8 ± 9.9 0.64
BMI (kg/m2) 29.0 ± 4.6 28.1 ± 5.7 26.2 ± 5.7 0.53
Baseline serum 25-OH vitD (nmol/L) 17.9 ± 4.9 18.0 ± 4.7 23.8 ± 6.9 0.03
Baseline serum PTH (pmol/L) 6.0 ± 3.2 6.5 ± 3.0 5.3 ± 4.9 0.25
Baseline U. Calcium/Cr (mmol/mmol) 0.37 ± 0.26 0.45 ± 2.7 0.50 ± 0.43 0.79
Post supplement serum 25-OH vitD (nmol/L) 23.3 ± 4.2 50.4 ± 11.4 90.1 ± 9.0 <0.0001
Post-supplementation serum PTH (pmol/L) 4.3 ± 2.0 5.1 ± 2.1 3.7 ± 0.77 0.21
Post-supplementation U. Calcium/Cr (mmol/mmol) 0.37 ± 0.21 0.47 ± 0.29 0.75 ± 0.42 0.07
Number of hypercalciurics pre-supplementation (U. Ca/Cr >0.6 mmol/L) 3 5 3
Total number of hypercalciurics post-supplementation 2 6 6
Number of new individuals developing hypercalciuria post-supplementation 1 2 3
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significantly different. Baseline serum 25-OH vitD con-
centration, however, was higher in the group that became 
replete. After supplementation, more women tended 
to reach the vitD replete status than men. U. Calcium/
Cr showed a rising trend, being the lowest in those who 
remained deficient and the highest in those who became 
replete. Statistical correlation, however, failed to reach sig-
nificance (p = 0.07). Proportion of individuals who became 
hypercalciuric (U. Calcium/Cr ≥0.6 mmol/L) after supple-
mentation was clearly highest in the replete group. 3 out 
of 6 normocalciurics became hypercalciuric (50%) with 
overall 6 out of 9 patients (66%) hypercalciuric post-sup-
plementation. Two out of 13 normocalciuric in the insuf-
ficient group developed hypercalciuria (15%) with the total 
of 6 out of 18 being hypercalciuric post-supplementation 
(33%). In the deficient group, 1 of 7 normocalciurics devel-
oped hypercalciuria (14%) with total 2 out of 10 being 
hypercalciuric post-supplementation (20%). As expected 
patients who became vitD replete had in average the lowest 
post-supplementation serum PTH concentration amongst 
the three groups, a decrement without clinical significance 
and confined to the normal range.     
Discussion
Clearly vitD deficiency is common in our ISF cohort; how-
ever, a comparison with a larger population study, even 
within the UK, is difficult because of an uneven distribu-
tion of ethnicity, socioeconomic status, and related pat-
terns of diet and sun exposure, as well as seasonal varia-
tion in serum 25-OH vitD levels. Poor standardization of 
the 25-OH vitD assays (ours included) is also an issue. 
Measurements using LC–MS/MS tend to be more accu-
rate. Immunoassays on the other hand have shown variable 
performance. A study comparing various immunoassays, 
however, showed that DiaSorin LIAISON (used in our 
study) was one of the better performing with high corre-
lation with LC–MS/MS methodology (concordance cor-
relation coefficient 0.95) and a relatively small bias (mean 
bias of 0.5 nmol/L) [25]. Besides the lack of standardiza-
tion, varying ‘cutoffs’ to define vitD deficiency also make 
comparisons difficult. A recent and large epidemiological 
study of >16,000 subjects in the UK found a prevalence 
of vitD deficiency of 15.5% during winter and spring 
using <25 nmol/L (<10 ng/mL) 25-OH vitD as the thresh-
old, but it included only the UK white population [23]. 
Another study in South London included >7000 subjects 
and reported a prevalence of vitD deficiency of 43%, but a 
serum 25-OH vitD level of <37.5 nmol/L (<15 ng/mL) was 
taken as deficient and included only the non-white popula-
tion [26]. Still, it is reasonable to conclude that vitD defi-
ciency in our mixed ethnicity population of ISF is common 
and not so different from the general UK population. We 
also found similar evidence of seasonal variation in the 
prevalence of vitD deficiency among our ISF cohort: while 
19.3% of those who had vitD measured in July, August, 
and September were found to be deficient (serum 25-OH 
vitD ≤30 nmol/L), 46.5% of those whose vitD levels were 
measured in January, February, and March were vitD defi-
cient (Fig. 1).
The theoretical risk of vitD supplementation stems from 
the view that increased hydroxylation to 1,25-OH vitD will 
increase gastrointestinal calcium absorption, leading sec-
ondarily to increased urinary calcium excretion, which may 
be exaggerated in ISFs (the so-called intestinal “hyperab-
sorbers”) [27]. In addition, it might also reduce intestinal 
binding of dietary oxalate (from reduced availability of 
intestinal calcium) and lead to increased oxalate absorption 
along the colon and thereby hyperoxaluria. Our comparison 
of the averaged serum and urinary measures made in vitD 
deficient and replete ISFs did not reveal any significant dif-
ferences, apart from lower serum PTH levels in the vitD 
replete group, which was not unexpected.
Supplementation with vitD3 did not result in significant 
increases in mean urinary excretion rates of calcium or oxa-
late overall, and there were also no significant differences in 
mean urinary excretion rate of citrate or in urinary pH val-
ues post-supplementation. However, there was a significant 
increase in urinary excretion of phosphate post-supplemen-
tation. Moreover, monitoring urinary calcium in individual 
patients did reveal an increase in some, notably those with 
lower baseline urinary calcium excretion (Fig. 2): about one 
quarter (6/26) of the normocalciuric ISFs became hypercal-
ciuric after having received a weekly oral load of vitD3 of 
20,000 IU administered for 4 months. This subgroup may 
well represent a physiologically distinct subpopulation 
within our ISF cohort, i.e., individuals with latent idiopathic 
hypercalciuria, the mechanism for which might be genetic 
(e.g., a CYP24A1 mutation or polymorphism [28] leading to 
intrinsic hypersensitivity to vitD as a consequence of ham-
pered degradation of 1,25-(OH) vitD by 1,25-(OH)2 vitD 
hydroxylase: genotyping such patients for CYP24A1 would 
be a reasonable next step to consider. Plotting the change 
in 24-h urine Calcium/Cr concentration ratios against the 
change in serum 25-OH vitD levels showed indeed a posi-
tive correlation (Fig. 3), potentially in keeping with the find-
ings of Taylor and colleagues that 1,25-(OH)2 vitD serum 
levels in ISFs tended to be higher than in healthy volunteers, 
although still within the normal range [21]; however, what 
may underlie this difference remains unclear. Similarly, it 
may not matter whether an arbitrary value defining hyper-
calciuria is exceeded, but rather that any increase in urine 
calcium may be associated with an increase in stone risk. 
It is worth noting that the vitamin D intervention carried 
out by Leaf and co-workers [17] did not find a correlation 
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between changes in urinary calcium and changes in serum 
25-OH vitD. This may be due to the fact that in our study the 
increase achieved in serum 25-OH vitD level was greater and 
revealed a decline in serum PTH-level post-supplementation, 
which was not been seen by Leaf et al. The difference may 
also be attributable to our use of vitD3 rather than vitD2, and 
to the regimen of supplementation used in our study, i.e., for 
4 vs. 2 months in the Leaf study. The initial serum 25-OH 
vitD concentration may also be important, since it is only 
when concentrations are <25 nmol/L (<10 ng/mL) that the 
levels of active 1,25-(OH)2 vitD are significantly reduced 
[18] and might be expected to increase more following vitD 
supplementation; however, we did not have access to a rou-
tine 1,25-(OH)2 vitD assay to explore this. Hypercalciu-
ria after vitD supplementation might also be modulated by 
therapeutic observance: indeed, average U. Calcium/Cr after 
supplementation was clearly higher in patients who success-
fully became vitD replete (6 out of 9 with hypercalciuria) vs. 
those who only became vitD insufficient (6 out of 18 with 
hypercalciuria) or vs. individuals who remained vitD defi-
cient (2 out of 10 with hypercalciuria). However, therapeutic 
compliance in itself was not monitored in this study.
A recent retrospective study has examined the effect of 
giving vitamin D and calcium supplementation to stone 
formers with reduced bone mineral density or hyperoxalu-
ria. The main findings were that an increase in mean serum 
25-OH vitD level (from 52.0 to 66.4 nmol/L, p < 0.001) 
was associated with a significant rise in mean urinary cal-
cium excretion (from 3.80 to 5.64 mmol/d, p < 0.001) and 
that 50% of hypercalciurics compared with 11.5% of nor-
mocalciurics (p = 0.038) developed stones during follow-
up [29]. Therefore, correction of vitD deficiency in idi-
opathic stone formers might not be without any risk.
Urinary urate excretion was slightly lower post-supple-
mentation. Whether the reduction in uric acid excretion is 
a chance finding or an effect of vitD3 supplementation is 
difficult to know; no previous studies have looked for such 
an association. It is possible that patients also followed 
advice on reducing animal protein intake (a well-known 
risk factor for kidney stones), although a comparison of 
24-h urea excretion (an index of animal protein intake [30]) 
did not show a significant difference pre- and post-sup-
plementations (Table 2). Urinary phosphate excretion was 
higher post-supplementation, which has been noted previ-
ously with vitD supplementation [31], and probably reflects 
increased intestinal absorption of phosphate [32]. Of itself, 
urinary phosphate is not a significant lithogenic factor [33], 
but recent studies linking phosphate intake, serum FGF23 
levels, kidney stone formation, and cardiovascular risk 
deserve more attention [21, 34].
We acknowledge that our study has several limita-
tions, including the small sample size, the relatively short 
duration of follow-up preventing adequate estimation of 
frequency of stone episodes post-intervention, and the non-
randomized design, as well as the lack of measurement of 
serum concentrations of 1,25-(OH)2 vitD and FGF23.
In summary, vitD deficiency was found to occur fre-
quently in our ISF cohort. On average, higher serum 
25-OH vitD levels were not associated with higher uri-
nary calcium, oxalate, citrate, phosphate, uric acid excre-
tion, or urinary pH. However, vitD3 administered orally 
for 4 months at a weekly dose of 20,000 IU was associated 
with an increase in both urinary calcium and phosphate as a 
function of the increment in serum 25 OH vitD concentra-
tion: about a quarter of the vitD3-supplemented normocal-
ciuric ISFs became hypercalciuric, and most of the patients 
who actually became vitD replete had hypercalciuria after 
supplementation.
In conclusion, we would recommend monitoring urinary 
calcium excretion in vitD-supplemented stone formers. 
Further studies are needed to determine whether there is 
any untoward consequence of a concomitant rise in intes-
tinal absorption and urinary excretion of phosphate associ-
ated with vitD supplementation in ISFs.
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